Hospital
Southcoast Hospitals Group, INC
Southcoast Hospitals Group, INC was paid $172.80M by Medicaid between Jan 2018 and Dec 2024, across 545 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.9% of everything it billed.
33Billing provider infoSOUTHCOAST HOSPITALS GROUP, INC
NEW BEDFORD, MA 02740
NEW BEDFORD, MA 02740
33aNPI1447275037assigned 07/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$172.80M
24GClaims4,878,292
24DCodes billed545
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#8 of 66
Median peer was paid$29.11M
This provider vs. median5.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 690,580 | $27.28M | |
| 2019 | 723,962 | $23.84M | |
| 2020 | 606,921 | $18.82M | |
| 2021 | 725,002 | $23.90M | |
| 2022 | 707,208 | $27.13M | |
| 2023 | 731,515 | $27.26M | |
| 2024incomplete | 693,104 | $24.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.9% | 99,798 | 90,895 | $17.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 92,727 | 80,801 | $14.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.0% | 79,105 | 71,336 | $12.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.2% | 29,521 | 25,403 | $10.63M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 105,516 | 32,341 | $7.85M |
| G0378 | Hospital observation service, per hour | 4.3% | 66,532 | 31,918 | $7.37M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.7% | 33,546 | 9,525 | $4.73M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 27,239 | 24,355 | $3.08M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 21,331 | 19,975 | $3.07M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 25,320 | 20,401 | $2.87M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 38,727 | 11,283 | $2.85M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 15,031 | 9,648 | $2.79M |
533 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 17,977 | $2.67M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 19,431 | $2.61M |
| S9485 | Crisis intervention mental health services, per diem | 1.5% | 5,013 | $2.59M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 12,690 | $2.46M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 13,614 | $2.35M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 33,696 | $2.32M |
| 59025 | Fetal non-stress test | 1.2% | 7,710 | $2.09M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 11,776 | $2.01M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 42,730 | $1.53M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,720 | $1.48M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 40,002 | $1.46M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56,609 | $1.45M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56,015 | $1.42M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 288,035 | $1.36M |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 22,255 | $1.34M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 8,519 | $1.31M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 7,325 | $1.31M |
| 64483 | <1% | 2,699 | $1.29M | |
| 80053 | Comprehensive metabolic panel | <1% | 256,404 | $1.12M |
| 93971 | <1% | 5,876 | $1.10M | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,178 | $1.09M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29,365 | $1.08M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 58,757 | $1.08M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,318 | $1.07M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,079 | $1.06M |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15,430 | $1.03M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,566 | $1.02M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,247 | $946K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,433 | $926K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16,985 | $812K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,503 | $810K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 9,362 | $769K |
| 81513 | <1% | 7,501 | $759K | |
| 76830 | Ultrasound, transvaginal | <1% | 5,730 | $622K |
| Q0081 | Infusion therapy, using other than chemotherapeutic drugs, per visit | <1% | 10,616 | $614K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 34,885 | $613K |
| 97161 | <1% | 9,899 | $593K | |
| 76642 | <1% | 5,453 | $585K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,691 | $584K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 21,007 | $563K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 642 | $563K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 989 | $523K |
| 84484 | <1% | 67,764 | $511K | |
| ATP14 | <1% | 66,434 | $500K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 18,288 | $490K |
| 83690 | <1% | 101,590 | $487K | |
| 76770 | <1% | 3,419 | $485K | |
| 80050 | General health panel | <1% | 31,727 | $481K |
| 70496 | <1% | 3,242 | $472K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 28,408 | $471K |
| 93970 | <1% | 1,888 | $462K | |
| 97162 | <1% | 8,364 | $453K | |
| 86481 | <1% | 7,490 | $437K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 54,161 | $435K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,787 | $414K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18,141 | $404K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,832 | $395K |
| 96415 | <1% | 2,050 | $390K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,350 | $380K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 63,135 | $366K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 98,834 | $366K |
| 97116 | <1% | 11,292 | $362K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 57,906 | $361K |
| 12001 | <1% | 1,770 | $353K | |
| 87480 | <1% | 21,950 | $340K | |
| 87660 | <1% | 21,951 | $338K | |
| 87510 | <1% | 21,947 | $337K | |
| 76536 | <1% | 2,874 | $335K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17,390 | $335K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 59,035 | $334K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 6,014 | $328K |
| 99218 | <1% | 1,191 | $290K | |
| 80061 | Lipid panel | <1% | 91,135 | $289K |
| 84702 | <1% | 22,797 | $283K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,720 | $278K |
| 93017 | <1% | 3,227 | $272K | |
| 86780 | <1% | 27,311 | $265K | |
| 87481 | <1% | 9,015 | $261K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12,362 | $260K |
| 87070 | <1% | 37,957 | $260K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,419 | $254K |
| 74018 | <1% | 6,926 | $250K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,019 | $242K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 265 | $240K |
| 88142 | <1% | 16,875 | $239K | |
| 71250 | <1% | 4,067 | $238K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,425 | $230K |
| 72100 | <1% | 7,513 | $226K | |
| 77080 | <1% | 3,595 | $224K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 47,979 | $223K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12,268 | $218K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,391 | $209K |
| 86803 | <1% | 20,287 | $207K | |
| 87536 | <1% | 4,726 | $206K | |
| 83880 | <1% | 12,341 | $196K | |
| 87653 | <1% | 6,564 | $191K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 53,500 | $188K |
| 10060 | <1% | 1,000 | $182K | |
| 84703 | <1% | 31,033 | $182K | |
| 94060 | <1% | 1,419 | $180K | |
| 97166 | <1% | 2,391 | $174K | |
| 82728 | <1% | 21,189 | $172K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 169,254 | $171K |
| 82607 | <1% | 19,931 | $164K | |
| 87400 | <1% | 9,331 | $161K | |
| 97165 | <1% | 2,221 | $158K | |
| 11045 | <1% | 623 | $155K | |
| 85610 | <1% | 65,581 | $152K | |
| 73130 | <1% | 6,807 | $142K | |
| 83735 | <1% | 35,539 | $142K | |
| 73630 | <1% | 7,440 | $141K | |
| 97803 | <1% | 1,176 | $140K | |
| 73610 | <1% | 6,760 | $137K | |
| 12011 | <1% | 708 | $135K | |
| 96367 | <1% | 4,482 | $133K | |
| 73030 | <1% | 6,982 | $130K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 9,265 | $130K |
| 87186 | <1% | 22,519 | $128K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,175 | $127K |
| 70486 | <1% | 2,633 | $125K | |
| 73560 | <1% | 3,189 | $123K | |
| 81001 | <1% | 50,424 | $119K | |
| 83550 | <1% | 22,424 | $118K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 152 | $117K |
| 86317 | <1% | 3,409 | $117K | |
| 83970 | <1% | 5,581 | $115K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,246 | $113K |
| 20610 | <1% | 1,059 | $113K | |
| 86235 | <1% | 2,284 | $112K | |
| 88342 | <1% | 3,573 | $112K | |
| 87340 | <1% | 13,658 | $107K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 16 | $107K |
| 86850 | <1% | 17,432 | $106K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,308 | $106K |
| 88112 | <1% | 3,043 | $105K | |
| 84439 | <1% | 18,070 | $104K | |
| 87521 | Neg quan hep c or qual rna | <1% | 3,974 | $100K |
| 82746 | <1% | 12,202 | $100K | |
| 82962 | <1% | 37,246 | $99K | |
| 70491 | <1% | 661 | $98K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,069 | $97K |
| 29848 | <1% | 57 | $94K | |
| 83540 | <1% | 23,711 | $94K | |
| 85730 | <1% | 20,307 | $93K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,173 | $93K |
| 76882 | <1% | 908 | $91K | |
| 77062 | <1% | 932 | $90K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,244 | $90K |
| 0001A | <1% | 3,559 | $90K | |
| 86706 | <1% | 11,982 | $88K | |
| 91300 | <1% | 210 | $87K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 12,481 | $85K |
| 73564 | <1% | 6,490 | $85K | |
| 80074 | <1% | 2,571 | $83K | |
| 76870 | <1% | 772 | $83K | |
| 12002 | <1% | 486 | $81K | |
| 73502 | <1% | 4,285 | $81K | |
| 0002A | <1% | 3,272 | $81K | |
| 72050 | <1% | 1,118 | $81K | |
| 92523 | <1% | 568 | $78K | |
| 77061 | <1% | 767 | $78K | |
| 73110 | <1% | 3,636 | $76K | |
| 87088 | <1% | 13,286 | $76K | |
| 87147 | <1% | 13,519 | $75K | |
| 85027 | <1% | 20,163 | $74K | |
| 70498 | <1% | 3,338 | $74K | |
| 86141 | <1% | 9,077 | $73K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,078 | $72K |
| 86003 | <1% | 1,064 | $70K | |
| 87040 | <1% | 7,523 | $69K | |
| 86360 | <1% | 3,383 | $68K | |
| 92567 | <1% | 536 | $66K | |
| 97802 | <1% | 419 | $64K | |
| ATP17 | <1% | 19,834 | $62K | |
| 86762 | <1% | 5,088 | $61K | |
| 84403 | <1% | 3,310 | $61K | |
| ATP08 | <1% | 16,063 | $61K | |
| 87902 | <1% | 437 | $57K | |
| 90715 | <1% | 3,050 | $57K | |
| 81003 | <1% | 32,239 | $57K | |
| 83605 | <1% | 7,764 | $56K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 28,240 | $56K |
| 97597 | <1% | 1,196 | $56K | |
| 87077 | <1% | 11,785 | $55K | |
| 86618 | <1% | 4,722 | $55K | |
| 86359 | <1% | 3,378 | $55K | |
| 82803 | <1% | 3,755 | $53K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 44,093 | $52K |
| 96376 | <1% | 7,731 | $52K | |
| 87808 | <1% | 5,213 | $52K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,600 | $51K |
| 86900 | <1% | 18,040 | $49K | |
| 85379 | <1% | 6,955 | $49K | |
| 47562 | <1% | 24 | $47K | |
| 84153 | <1% | 4,611 | $45K | |
| 94729 | <1% | 1,042 | $45K | |
| 83655 | <1% | 4,172 | $44K | |
| 86038 | <1% | 5,541 | $44K | |
| 64493 | <1% | 241 | $43K | |
| 86901 | <1% | 17,983 | $43K | |
| 86704 | <1% | 4,409 | $43K | |
| 82043 | <1% | 15,392 | $43K | |
| 71271 | <1% | 1,024 | $43K | |
| 83516 | <1% | 4,616 | $42K | |
| 80076 | <1% | 11,780 | $42K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 234 | $42K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 252 | $41K |
| 86160 | <1% | 3,074 | $41K | |
| 87338 | <1% | 3,830 | $39K | |
| 83615 | <1% | 17,940 | $39K | |
| 0031A | <1% | 1,363 | $39K | |
| 86376 | <1% | 3,684 | $39K | |
| 72070 | <1% | 969 | $38K | |
| 81025 | <1% | 6,666 | $38K | |
| J2704 | Injection, propofol, 10 mg | <1% | 23,399 | $37K |
| 84550 | <1% | 22,153 | $37K | |
| 73080 | <1% | 2,305 | $37K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 15,817 | $37K |
| 62323 | <1% | 270 | $36K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 37,375 | $36K |
| 82784 | <1% | 4,993 | $34K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 26 | $34K |
| 73140 | <1% | 1,384 | $34K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,346 | $34K |
| 84112 | <1% | 449 | $34K | |
| 29125 | <1% | 323 | $33K | |
| 84146 | <1% | 2,413 | $33K | |
| 86708 | <1% | 4,117 | $33K | |
| 71101 | <1% | 1,296 | $32K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 4,277 | $32K |
| 82274 | <1% | 2,852 | $31K | |
| 58661 | <1% | 13 | $30K | |
| ATP15 | <1% | 4,916 | $30K | |
| 83001 | <1% | 1,956 | $29K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 775 | $27K |
| 88307 | <1% | 588 | $27K | |
| ATP03 | <1% | 8,766 | $26K | |
| 36430 | <1% | 131 | $25K | |
| 93225 | <1% | 390 | $25K | |
| 87468 | <1% | 1,801 | $25K | |
| 87484 | <1% | 1,804 | $25K | |
| 87469 | <1% | 1,801 | $25K | |
| 87478 | <1% | 1,796 | $25K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,176 | $24K |
| 0004A | <1% | 735 | $24K | |
| 87046 | <1% | 1,959 | $24K | |
| 88304 | <1% | 3,528 | $24K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,893 | $24K |
| 92587 | <1% | 150 | $24K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,247 | $24K |
| 87450 | <1% | 3,777 | $23K | |
| 85652 | <1% | 13,617 | $23K | |
| 86225 | <1% | 2,543 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 37,686 | $23K |
| 87210 | <1% | 5,889 | $22K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 28 | $22K |
| 83721 | <1% | 4,011 | $22K | |
| 82570 | <1% | 6,553 | $22K | |
| 87205 | <1% | 7,726 | $21K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 106 | $21K |
| 94727 | <1% | 257 | $21K | |
| 84481 | <1% | 1,739 | $20K | |
| 82550 | <1% | 7,908 | $20K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,492 | $20K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,416 | $20K |
| 80164 | <1% | 3,780 | $20K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 84 | $19K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,316 | $19K |
| ATP16 | <1% | 2,963 | $19K | |
| 86709 | <1% | 2,839 | $19K | |
| 93226 | <1% | 469 | $18K | |
| 86431 | <1% | 4,534 | $18K | |
| 73590 | <1% | 1,211 | $18K | |
| 83520 | <1% | 2,128 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,300 | $17K |
| 87625 | <1% | 632 | $17K | |
| 74019 | <1% | 360 | $16K | |
| 84402 | <1% | 682 | $16K | |
| 87427 | <1% | 1,773 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,544 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,083 | $14K |
| 84425 | <1% | 1,178 | $14K | |
| 85018 | <1% | 6,206 | $14K | |
| 94726 | <1% | 229 | $14K | |
| 84156 | <1% | 5,327 | $14K | |
| 83883 | <1% | 1,543 | $14K | |
| 91307 | <1% | 34 | $14K | |
| 62321 | <1% | 79 | $14K | |
| 83525 | <1% | 1,240 | $14K | |
| 97035 | <1% | 185 | $13K | |
| 85007 | <1% | 6,441 | $13K | |
| 82565 | <1% | 6,898 | $13K | |
| 82950 | <1% | 2,941 | $13K | |
| 84460 | <1% | 8,810 | $12K | |
| 87449 | <1% | 1,754 | $12K | |
| 86140 | <1% | 3,739 | $12K | |
| 87045 | <1% | 1,774 | $12K | |
| 73700 | <1% | 243 | $12K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,174 | $12K |
| 82140 | <1% | 1,604 | $12K | |
| 87209 | <1% | 843 | $12K | |
| 84100 | <1% | 6,605 | $12K | |
| 85014 | <1% | 5,277 | $12K | |
| 91305 | <1% | 29 | $12K | |
| 84450 | <1% | 8,198 | $12K | |
| 83002 | <1% | 728 | $11K | |
| 76000 | <1% | 275 | $11K | |
| 0064A | <1% | 513 | $11K | |
| 82105 | <1% | 1,114 | $11K | |
| 82670 | <1% | 454 | $11K | |
| 0071A | <1% | 264 | $11K | |
| 86787 | <1% | 1,030 | $10K | |
| 87324 | <1% | 1,438 | $10K | |
| 77336 | <1% | 241 | $10K | |
| 87507 | <1% | 28 | $10K | |
| 87015 | <1% | 2,142 | $10K | |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 14 | $10K |
| 0054A | <1% | 426 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,736 | $9K |
| 86800 | <1% | 676 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 191 | $9K |
| 80178 | <1% | 2,753 | $9K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 554 | $9K |
| 86705 | <1% | 890 | $9K | |
| 88341 | <1% | 694 | $9K | |
| 84165 | <1% | 1,806 | $9K | |
| 82947 | <1% | 4,178 | $8K | |
| 83010 | <1% | 852 | $8K | |
| 0072A | <1% | 206 | $8K | |
| 88302 | <1% | 324 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,154 | $8K |
| 86765 | <1% | 827 | $8K | |
| 0012A | <1% | 332 | $8K | |
| 85045 | <1% | 2,419 | $8K | |
| 77002 | <1% | 61 | $8K | |
| 86735 | <1% | 756 | $7K | |
| 86200 | <1% | 766 | $7K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 449 | $7K |
| ATP09 | <1% | 1,383 | $7K | |
| 82951 | <1% | 592 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 147 | $7K |
| 82248 | <1% | 4,111 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,498 | $7K |
| ATP07 | <1% | 1,558 | $7K | |
| 0011A | <1% | 350 | $6K | |
| 82172 | <1% | 399 | $6K | |
| ATP02 | <1% | 1,553 | $6K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,570 | $6K |
| 86361 | <1% | 419 | $6K | |
| 83921 | <1% | 531 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,423 | $6K |
| 62370 | <1% | 290 | $6K | |
| 87177 | <1% | 839 | $6K | |
| 73090 | <1% | 466 | $6K | |
| 82150 | <1% | 1,187 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,859 | $6K |
| 96368 | <1% | 369 | $5K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 29 | $5K |
| 82977 | <1% | 1,727 | $5K | |
| 76801 | <1% | 25 | $5K | |
| 86665 | <1% | 162 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,933 | $5K |
| 87535 | <1% | 161 | $5K | |
| 86039 | <1% | 490 | $5K | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 1,579 | $4K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,559 | $4K |
| 82952 | <1% | 654 | $4K | |
| ATP18 | <1% | 1,715 | $4K | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 2,271 | $4K |
| 92610 | <1% | 144 | $4K | |
| 86334 | <1% | 518 | $4K | |
| 90686 | <1% | 628 | $4K | |
| 87420 | <1% | 371 | $4K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,102 | $4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 916 | $4K |
| ATP11 | <1% | 1,457 | $4K | |
| 0003A | <1% | 237 | $4K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 20,042 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 741 | $3K |
| G0008 | Administration of influenza virus vaccine | <1% | 631 | $3K |
| 82040 | <1% | 3,141 | $3K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,945 | $3K |
| ATP10 | <1% | 1,049 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 5,168 | $3K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 744 | $3K |
| 85384 | <1% | 586 | $3K | |
| 0124A | <1% | 118 | $3K | |
| 86617 | <1% | 130 | $3K | |
| 73552 | <1% | 181 | $3K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,204 | $3K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,401 | $3K |
| 29515 | <1% | 13 | $3K | |
| 0052A | <1% | 72 | $3K | |
| 72081 | <1% | 16 | $3K | |
| 84155 | <1% | 1,938 | $3K | |
| 93798 | <1% | 219 | $3K | |
| 0051A | <1% | 69 | $3K | |
| 86664 | <1% | 185 | $3K | |
| 85651 | <1% | 1,032 | $3K | |
| 93308 | <1% | 15 | $3K | |
| 93000 | <1% | 331 | $3K | |
| 84520 | <1% | 3,471 | $3K | |
| 80177 | <1% | 425 | $2K | |
| 74175 | <1% | 151 | $2K | |
| 88173 | <1% | 44 | $2K | |
| ATP05 | <1% | 621 | $2K | |
| 88185 | <1% | 40 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 109 | $2K |
| 80069 | <1% | 771 | $2K | |
| 86663 | <1% | 160 | $2K | |
| 82247 | <1% | 1,505 | $2K | |
| 82378 | <1% | 254 | $2K | |
| 82785 | <1% | 109 | $2K | |
| 86308 | <1% | 400 | $2K | |
| 73523 | <1% | 38 | $2K | |
| 90674 | <1% | 136 | $2K | |
| 86923 | <1% | 102 | $2K | |
| 86696 | <1% | 84 | $2K | |
| 86769 | <1% | 38 | $2K | |
| 88300 | <1% | 119 | $2K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 97163 | <1% | 50 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 285 | $1K |
| 70487 | <1% | 15 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,227 | $1K |
| 88184 | <1% | 26 | $1K | |
| 17250 | <1% | 24 | $1K | |
| 87255 | <1% | 45 | $1K | |
| 0134A | <1% | 41 | $1K | |
| 74174 | <1% | 13 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,720 | $1K |
| 82533 | <1% | 96 | $1K | |
| 92579 | <1% | 327 | $1K | |
| 72040 | <1% | 29 | $1K | |
| 84132 | <1% | 743 | $912.71 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 12,701 | $894.73 |
| 86593 | <1% | 292 | $892.14 | |
| 72170 | <1% | 128 | $882.92 | |
| ATP04 | <1% | 152 | $794.16 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,208 | $762.58 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 266 | $740.50 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 242 | $694.20 |
| 87563 | <1% | 26 | $680.90 | |
| 87150 | <1% | 38 | $640.20 | |
| ATP19 | <1% | 340 | $581.91 | |
| 86695 | <1% | 44 | $530.34 | |
| 84075 | <1% | 608 | $502.90 | |
| 72131 | <1% | 12 | $496.05 | |
| 64494 | <1% | 122 | $466.72 | |
| 82465 | <1% | 94 | $459.12 | |
| 89051 | <1% | 131 | $458.44 | |
| 86255 | <1% | 38 | $454.88 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 183 | $429.02 |
| 76937 | <1% | 78 | $407.40 | |
| 84270 | <1% | 29 | $383.29 | |
| 96417 | <1% | 399 | $371.80 | |
| 96523 | <1% | 32 | $363.24 | |
| 83993 | <1% | 31 | $342.41 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 268 | $312.53 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 423 | $299.52 |
| 73660 | <1% | 12 | $271.90 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 341 | $271.24 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 157 | $271.17 |
| 86756 | <1% | 27 | $269.67 | |
| 87081 | <1% | 43 | $249.66 | |
| 84144 | <1% | 12 | $228.36 | |
| 82390 | <1% | 24 | $226.55 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 250 | $196.79 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,518 | $184.22 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $177.66 |
| 87109 | <1% | 12 | $162.84 | |
| 87329 | <1% | 14 | $151.10 | |
| 87328 | <1% | 14 | $150.20 | |
| 80202 | <1% | 19 | $143.28 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 492 | $139.19 |
| 0013A | <1% | 22 | $137.61 | |
| 82330 | <1% | 12 | $134.37 | |
| 87207 | <1% | 29 | $125.65 | |
| 86021 | <1% | 25 | $119.43 | |
| 73060 | <1% | 16 | $115.26 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 279 | $113.94 |
| 90653 | <1% | 18 | $100.20 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 63 | $94.60 |
| 84479 | <1% | 12 | $80.44 | |
| 80175 | <1% | 25 | $72.94 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 275 | $69.54 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 105 | $44.32 |
| C1769 | Guide wire | <1% | 709 | $43.82 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 695 | $41.36 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 232 | $36.71 |
| 80185 | <1% | 12 | $13.67 | |
| C1755 | Catheter, intraspinal | <1% | 1,677 | $8.55 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 16 | $2.36 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,701 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 185 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 422 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 133 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,360 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 578 | $0.00 |
| 84145 | 0% | 122 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 1,255 | $0.00 |
| 99152 | 0% | 648 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 287 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 94 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 326 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 95 | $0.00 |
| 94664 | 0% | 260 | $0.00 | |
| 86036 | 0% | 13 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 47 | $0.00 |
| 90661 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 78 | $0.00 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 12 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 43 | $0.00 |
| C1729 | Catheter, drainage | 0% | 15 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 82 | $0.00 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 0% | 1,264 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 728 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 208 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 224 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 26 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 502 | $0.00 |
| 94760 | 0% | 451 | $0.00 | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 68 | $0.00 |
| 97014 | 0% | 29 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 97 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 14 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 180 | $0.00 |
| 99292 | 0% | 12 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 99 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 27 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIGG, WILLIAM (EXECUTIVE VICE PRESIDENT & CFO)
Parent organizationSOUTHCOAST HEALTH SYSTEM, INC
| Provider | Location | Paid |
|---|---|---|
| Southcoast Hospitals Group, INC | Fall River, MA | $97.65M |
| Southcoast Hospitals Group, INC | Wareham, MA | $26.22M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.